{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:41:40Z","timestamp":1790361700855,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1097\/pas.0000000000000542","type":"journal-article","created":{"date-parts":[[2015,10,8]],"date-time":"2015-10-08T12:15:33Z","timestamp":1444306533000},"page":"253-261","source":"Crossref","is-referenced-by-count":50,"title":["High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis"],"prefix":"10.1097","volume":"40","author":[{"given":"Shaoying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian L.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth A.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Cameron","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishitha M.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210131","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2010.08159.x","article-title":"Advances in the understanding of MYC-induced lymphomagenesis.","volume":"149","author":"Klapproth","year":"2010","journal-title":"Br J Haematol"},{"key":"R2-11-20210131","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/PAP.0b013e3182a289f2","article-title":". MYCBCL2 double-hit high-grade B-Cell lymphoma.","volume":"20","author":"Li","year":"2013","journal-title":"Adv Anat Pathol"},{"key":"R3-11-20210131","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2006.07.014","article-title":". The c-Myc target gene network.","volume":"16","author":"Dang","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"R4-11-20210131","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1038\/sj.onc.1207261","article-title":"Myc pathways provoking cell suicide and cancer.","volume":"22","author":"Nilsson","year":"2003","journal-title":"Oncogene"},{"key":"R5-11-20210131","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":". Double-hit B-cell lymphomas.","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"key":"R6-11-20210131","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/modpathol.2011.147","article-title":". B-cell lymphomas with MYC8q24 rearrangements and IGHBCL2t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"key":"R7-11-20210131","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3324\/haematol.2008.005355","article-title":". Clinicopathological features of lymphomaleukemia patients carrying both BCL2 and MYC translocations.","volume":"94","author":"Tomita","year":"2009","journal-title":"Haematologica"},{"key":"R8-11-20210131","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":". Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"R10-11-20210131","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1182\/blood.V90.10.4078","article-title":". Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkins lymphoma.","volume":"90","author":"Koduru","year":"1997","journal-title":"Blood"},{"key":"R11-11-20210131","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1080\/10428190410001713170","article-title":". Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature.","volume":"45","author":"Kerbauy","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"R12-11-20210131","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":". Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"R13-11-20210131","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","article-title":". Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.","volume":"119","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"R14-11-20210131","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1309\/YHFE-R65B-D3LK-3GGV","article-title":". Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas.","volume":"113","author":"Chang","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"R15-11-20210131","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/10428194.2014.907896","article-title":". TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.","volume":"56","author":"Gebauer","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R16-11-20210131","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1309\/AJCPPHMZ6VHF0WQV","article-title":". p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.","volume":"141","author":"Xie","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"R17-11-20210131","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":". Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"key":"R18-11-20210131","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/modpathol.2014.95","article-title":". B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYCBCL2 double-hit lymphomas.","volume":"28","author":"Li","year":"2015","journal-title":"Mod Pathol"},{"key":"R19-11-20210131","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/PAS.0000000000000433","article-title":". MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYCBCL2 protein double-positive diffuse large B-cell lymphoma.","volume":"39","author":"Wang","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R20-11-20210131","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/modpathol.2014.95","article-title":". B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYCBCL2 double-hit lymphomas.","volume":"28","author":"Li","year":"2015","journal-title":"Mod Pathol"},{"key":"R22-11-20210131","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":". Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"R23-11-20210131","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":". MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"key":"R24-11-20210131","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/modpathol.2013.214","article-title":". Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.","volume":"27","author":"Tzankov","year":"2014","journal-title":"Mod Pathol"},{"key":"R25-11-20210131","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","article-title":". MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.","volume":"98","author":"Valera","year":"2013","journal-title":"Haematologica"},{"key":"R26-11-20210131","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3324\/haematol.2013.091827","article-title":". Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.","volume":"99","author":"Aukema","year":"2014","journal-title":"Haematologica"},{"key":"R28-11-20210131","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2007-02-072082","article-title":". Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.","volume":"110","author":"Young","year":"2007","journal-title":"Blood"},{"key":"R29-11-20210131","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJM199708213370804","article-title":". Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.","volume":"337","author":"Ichikawa","year":"1997","journal-title":"N Engl J Med"},{"key":"R30-11-20210131","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":". Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, Doxorubicin, vincristine, and prednisone.","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000000542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:45:52Z","timestamp":1620967552000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201602000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000000542","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}